Mass spectrometry platforms have attracted a lot of interest in the last 2 decades as profiling
tools for native peptides and proteins with clinical potential. However, limitations associated …

Proteomic biomarkers offer the hope of improving the management of patients with kidney
diseases by enabling more accurate and earlier detection of renal pathology than is …

Progressive CKD is generally detected at a late stage by a sustained decline in eGFR and/or
the presence of significant albuminuria. With the aim of early and improved risk stratification …

Background. Chronic kidney disease (CKD) progression is currently assessed by a decline
in estimated glomerular filtration rate (eGFR) and/or an increase in urinary albumin excretion …

Biomarker research is continuously expanding in the field of clinical proteomics. A
combination of different proteomic–based methodologies can be applied depending on the …

Background In spite of its invasive nature and risks, kidney biopsy is currently required for
precise diagnosis of many chronic kidney diseases (CKDs). Here, we explored the …

Background Diabetic nephropathy (DN) is one of the major late complications of diabetes.
Treatment aimed at slowing down the progression of DN is available but methods for early …

Chronic kidney disease (CKD) is a prevalent cause of morbidity and mortality worldwide. A
hallmark of CKD progression is renal fibrosis characterized by excessive accumulation of …

Peptides carry important functions in normal physiological and pathophysiological
processes and can serve as clinically useful biomarkers. Given the ability to diffuse …

Capillary electrophoresis coupled with mass spectrometry (CE-MS) has been used as a
platform for discovery and validation of urinary peptides associated with chronic kidney …